MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.940
-0.010 (-0.51%)
Nov 21, 2024, 11:38 AM EST - Market open
MediciNova Employees
MediciNova had 13 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$791,845
Market Cap
95.15M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
EDAP TMS | 307 |
Coherus BioSciences | 306 |
Invivyd | 95 |
HilleVax | 90 |
Genelux | 23 |
Annovis Bio | 16 |
Genenta Science | 14 |
FibroBiologics | 10 |
MNOV News
- 6 days ago - MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver - GlobeNewsWire
- 9 days ago - MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis - GlobeNewsWire
- 4 weeks ago - MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) - GlobeNewsWire
- 7 weeks ago - MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) - GlobeNewsWire
- 2 months ago - MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND - GlobeNewsWire
- 2 months ago - MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting - GlobeNewsWire
- 2 months ago - MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition - GlobeNewsWire
- 5 months ago - MediciNova Chief Business Officer David H. Crean, Ph.D. - GlobeNewsWire